Metabolomic analysis of a selective ABCA1 inducer in obesogenic challenge provides a rationale for therapeutic development

BACKGROUND: Therapeutic agents with novel mechanisms of action are needed to combat the growing epidemic of type 2 diabetes (T2D) and related metabolic syndromes. Liver X receptor (LXR) agonists possess preclinical efficacy yet produce side effects due to excessive lipogenesis. Anticipating that man...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewandowski, Cutler T., Khan, Md.Wasim, BenAissa, Manel, Dubrovskyi, Oleksii, Ackerman-Berrier, Martha, LaDu, Mary Jo, Layden, Brian T., Thatcher, Gregory R.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010624/
https://www.ncbi.nlm.nih.gov/pubmed/33752129
http://dx.doi.org/10.1016/j.ebiom.2021.103287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010624/
https://www.ncbi.nlm.nih.gov/pubmed/33752129
http://dx.doi.org/10.1016/j.ebiom.2021.103287

Ejemplares similares